• KORTUC

  Led · Equity · Jun 2026

  KORTUC develops KRC-01, an intratumoral radiosensitizer that uses hydrogen peroxide as the active ingredient and sodium hyaluronate to maintain elevated tumor oxygenation for up to 48 hours after injection. The company reports KRC-01 inactivates antioxidative enzymes within tumors to reduce hypoxia and increase sensitivity to radiation therapy. A Phase 1/2 clinical trial led by the University of California San Diego has launched under an FDA-reviewed protocol and will enroll 70 patients (10 in Phase 1 and 60 in Phase 2) to evaluate safety and potential overall survival benefit in locally advanced cervical cancer. The study will begin in the U.S. with planned expansion to the U.K. and India. KORTUC is headquartered in Palo Alto and was originally founded in Japan. The company is also studying its technology in other solid tumor indications, including breast cancer, and recently closed a $20 million funding round led by Midas Capital to advance its clinical program.

• SetPoint Medical

  Participated · Series D · Aug 2025

  SetPoint Medical is a commercial-stage medical technology company headquartered in Valencia, Calif., focused on therapies for chronic autoimmune diseases. Its FDA‑approved SetPoint System is the first neuroimmune modulation therapy for adults with moderate-to-severe rheumatoid arthritis, providing a device-based alternative for patients who do not respond to or cannot tolerate biologic or targeted drug therapies. The company’s proprietary integrated neurostimulation platform is designed to activate innate anti-inflammatory pathways in the vagus nerve to reduce inflammation and restore immunologic setpoint. Proceeds from the recent financing will support commercialization of the SetPoint System in select U.S. markets this year and broader national expansion in 2026, and will also fund advancement of the company’s pipeline in other autoimmune conditions. SetPoint plans to evaluate its platform for additional indications including multiple sclerosis and Crohn’s disease. In conjunction with the fundraise the company expanded its leadership team and board to support commercialization and market access efforts. SetPoint Medical is a privately held clinical-stage healthcare company focused on treating chronic autoimmune diseases. The company is developing a novel platform that stimulates the vagus nerve to activate the inflammatory reflex and produce a systemic immune-restorative effect. The SetPoint system is a miniaturized stimulation device placed on the vagus nerve through a small incision on the left side of the neck in an outpatient procedure and delivers stimulation on a preset schedule. The platform is being developed as an alternative for patients with rheumatoid arthritis who have an incomplete response to or are intolerant of biologic drugs, and is also intended for inflammatory bowel disease and other chronic autoimmune conditions. SetPoint is advancing the RESET-RA study and preparing U.S. FDA regulatory submissions and early commercialization for the RA indication. Financially, the company recently announced an $80 million equity financing and expanded a senior secured term loan facility of up to $65 million with Runway Growth Capital to support development and early commercial activities. SetPoint Medical develops a bioelectronic medicine platform designed to stimulate the vagus nerve and activate the body’s inflammatory reflex to produce a systemic immune‑restorative effect for chronic autoimmune diseases. The company is pursuing electrical‑pulse therapies as a potentially safer, lower‑cost alternative to drugs and biologics for conditions including rheumatoid arthritis and inflammatory bowel disease. SetPoint is clinical‑stage and is advancing its technology through the RESET‑RA study, which will evaluate safety and efficacy in patients with moderate‑to‑severe RA. The $35 million financing announced will support the ongoing RESET‑RA trial and other development activities. SetPoint is privately held, was founded in 2007, and is based in Valencia, California. The articles do not disclose revenue or user metrics. SetPoint Medical is a privately held, clinical‑stage bioelectronic medicine company developing a platform that stimulates the vagus nerve to activate the inflammatory reflex and reduce systemic inflammation. The company is initially focused on a less immunosuppressive therapeutic option for patients with rheumatoid arthritis (RA) and is also developing applications for inflammatory bowel disease and other chronic autoimmune conditions. SetPoint’s investigational device is intended to offer an alternative to biologic and targeted drug therapies with potentially lower risk and cost. The company has received Breakthrough Device designation from the U.S. FDA for use in RA patients who are incomplete responders to, or intolerant of, multiple biologic drugs. Proceeds from the financing will support the RESET‑RA multicenter, double‑blind, randomized, sham‑controlled pivotal trial that will enroll up to 250 patients at 40 U.S. sites to evaluate safety and effectiveness. SetPoint converts neurostimulation of the vagus nerve into a systemic immune‑restorative effect and is positioning its platform toward regulatory‑pathway clinical validation. SetPoint Medical is developing a proprietary bioelectronic medicine platform that uses a small implanted device to activate the body’s Inflammatory Reflex and produce a systemic anti-inflammatory effect. The company’s core product is an implanted stimulator that targets the vagus nerve as an alternative to drug therapies for chronic inflammatory diseases. SetPoint has published positive results from a first‑in‑human proof‑of‑concept trial in rheumatoid arthritis in PNAS and presented positive data at the American College of Rheumatology meeting. The company positions its approach as potentially lower risk and lower cost compared with current biologic treatments. SetPoint plans to use the new financing to advance clinical development and enable its next clinical trial in rheumatoid arthritis. It is a privately held company focused on commercializing bioelectronic medicines for debilitating inflammatory diseases.

• Sova Health

  Participated · Seed · Jun 2024

  Sova Health develops gut-focused healthcare products and programmes, including gut microbiome tests and probiotic supplements. The company targets common conditions such as irritable bowel syndrome, acidity, constipation, and bloating. It will use recent funding to advance product development, hire talent, and expand its presence across geographies. Sova Health was founded by Tanveer Singh and Max Kushnir. The startup previously raised pre-seed backing from Goodwater Capital, Brinc, IIMA Ventures, and Stanford Angels. Current public reporting does not disclose revenue or user metrics for Sova Health.

• Corsair Pharma

  Participated · Series B · Sep 2023

  Corsair Pharma is a private biopharmaceutical company focused on developing prodrugs of treprostinil for treatment of PAH. Its core product is a once-daily transdermal patch intended to provide continuous and consistent blood levels of treprostinil comparable to an infusion pump. The patch delivers an inactive prodrug designed to cross the skin, enter the bloodstream, and convert rapidly to treprostinil in the liver. The company is focused on improving the therapeutic profile of medications and providing treatment options for patients. Led by Bobby Singh, Ph.D., President, CEO and Director, Corsair is advancing the patch through clinical development. The company recently completed a Series B financing to support clinical advancement of its program.

No current team members are available.